Compare BioNano Genomics Inc (BNGO) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Ralph Lauren Corp — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Ralph Lauren Corp trades at $368.3 (market cap $21.96B). The key difference: Ralph Lauren Corp is far larger — about 1663.6× BioNano Genomics Inc's market cap, and Ralph Lauren Corp pays a 1.01% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | RL | |
|---|---|---|
Market Cap | $13.20M | $21.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $414.25 |
52-Week Low | $1.09 | $283.34 |
Enterprise Value | $15.81M | $22.90B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Ralph Lauren (RL) trades at $374.49, down 5.17% on the day, showing bearish technical momentum despite strong fundamentals. The company demonstrates robust financial performance with consistent earnings beats, including Q1 2026 EPS of $2.80 beating expectations of $2.55. Revenue growth accelerated to $7.08 billion in 2025 with net income margin expanding to 10.49%. Analyst consensus remains strongly bullish with 66% buy ratings and a $446.25 price target representing 19% upside potential.
The stock presents a compelling growth opportunity with strong brand momentum and digital expansion driving performance, though premium valuation metrics and technical bearish signals warrant caution. Key risks include macroeconomic sensitivity and competitive pressures in the apparel sector, while institutional sentiment remains positive given the company's execution on its Next Great Chapter strategy and Asia growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
